Subscribe To
Alpha architect switches etfs to active management
Alpha Architect is switching its ETFs over to active management. Effective Monday, the Alpha Architect...
February 1, 2022, 5:01 pm
Alpha architect switches etfs to active management
Alpha Architect is switching its ETFs over to active management. Effective Monday, the Alpha Architect...
February 1, 2022, 5:01 pm
Apple hits record revenue as iphone sales defy supply chain shortages
After ditching guidance at the beginning of the pandemic, Apple had plenty of reason to smile as it rep...
January 27, 2022, 5:10 pm
Apple hits record revenue as iphone sales defy supply chain shortages
After ditching guidance at the beginning of the pandemic, Apple had plenty of reason to smile as it rep...
January 27, 2022, 5:10 pm
Apple hits record revenue as iphone sales defy supply chain shortages
After ditching guidance at the beginning of the pandemic, Apple had plenty of reason to smile as it rep...
January 27, 2022, 5:10 pm
A pair of undervalued insurers offering double-digit returns
The insurance industry can be cutthroat as customers face very little in the way of switching costs whe...
December 26, 2021, 3:47 pm
A pair of undervalued insurers offering double-digit returns
The insurance industry can be cutthroat as customers face very little in the way of switching costs whe...
December 26, 2021, 3:47 pm
A pair of undervalued insurers offering double-digit returns
The insurance industry can be cutthroat as customers face very little in the way of switching costs whe...
December 26, 2021, 3:47 pm
3 stocks to buy after the fed's last 2021 update
The last Fed event is out of the way and markets are itching to break even higher records. This is cond...
December 16, 2021, 1:28 pm
3 stocks to buy after the fed's last 2021 update
The last Fed event is out of the way and markets are itching to break even higher records. This is cond...
December 16, 2021, 1:28 pm
3 stocks to buy after the fed's last 2021 update
The last Fed event is out of the way and markets are itching to break even higher records. This is cond...
December 16, 2021, 1:28 pm
Why did shares of docusign drop 11.5% in november?
Investors are ditching stay-at-home stocks and their unsustainable valuations....
December 8, 2021, 8:55 pm
Why did shares of docusign drop 11.5% in november?
Investors are ditching stay-at-home stocks and their unsustainable valuations....
December 8, 2021, 8:55 pm
Why did shares of docusign drop 11.5% in november?
Investors are ditching stay-at-home stocks and their unsustainable valuations....
December 8, 2021, 8:55 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm